There’s a saying in Brussels called going ‘into the tunnel’. It’s when negotiators get together to try to plot a path to resolving Brexit. As the political turmoil continues, one certainty is that pharmaceutical innovators have been meticulously planning for Brexit. For two years or more, they have been reorganising supply chains and revising regulatory approvals. This work is critical in minimising the risk of disruption to the supply of medicines to patients after March 29th.